Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PR Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $275.4 million, up 27% year over year
- ➤2026 revenue guidance raised to $1.04-$1.05 billion, up 28%-29%
- ➤Approximately 61,500 clinical cases completed, up approximately 21% year over year
- ➤Q3 net income $15.3 million, versus $24.3 million last year
- ➤Q3 operating cash flow used $22.2 million, versus $62.4 million provided last year
Expert Statements
David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences
“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year,”
David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences
“Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey.”
David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences
“Caris Assure® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.”
David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences
“It all comes back to making precision medicine a reality for every patient through a comprehensive, data-driven approach.”
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance PR Newswire
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests
Get started
Create a free account to read the full story.